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correct differential diagnosis is of paramount importance 
to avoid unnecessary surgical operations and to imple-
ment the appropriate treatment mainly in the uncommon 
forms of HH, such as nesidioblastosis and autoimmune 
hypoglycaemia.
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Abbreviations
HH  Hyperinsulinemic hypoglycaemia
pNET  Pancreatic neuroendocrine tumour
SSTR  Somatostatin receptors
INF-α  Interferon-α
TAE  Trans-arterial embolization
TACE  Trans-arterial chemoembolization
SIRT  Selective internal radiation therapy
PRRT  Peptide receptor radionuclide therapy
NIPHS  Noninsulinoma pancreatogenous hypoglycaemia 
syndrome
RYGB  Roux-en-Y gastric bypass
Classification and diagnostic overview
The hyperinsulinemic hypoglycaemia (HH) is a rare condi-
tion characterized by inappropriate insulin secretion in the 
presence of hypoglycaemia. It should be suspected in the 
presence of Whipple’s triad: symptoms or signs consistent 
with hypoglycaemia, low plasma glucose level and relief 
of symptoms after administration of glucose. Symptoms 
of hypoglycaemia are classified as neuroglycopenic due to 
brain glucose deprivation and autonomic due to adrenergic 
activation. The first group ranges from dizziness, mental 
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confusion, abnormal behaviour to epilepsy and coma; the 
second group comprises adrenergic symptoms such as pal-
pitations, tremor, anxiety and cholinergic symptoms such 
as sweating, hunger and paresthesias [1, 2]. In 2009, the 
Endocrine Society’s guidelines for evaluation and manage-
ment of hypoglycaemic disorders established a new clas-
sification, no longer based on the timing of the hypogly-
caemic symptoms, i.e. fasting versus postprandial, but on 
the patients’ health status [3]. Consequently, HH should 
be suspected in an apparently healthy patient after exclu-
sion of drug assumption, hormonal deficiency, critical ill-
ness or nonislet cell tumours. The most common cause of 
HH in adults is the insulinoma, a generally benign pan-
creatic neuroendocrine tumour (pNET) with an incidence 
of 4 cases  per million per year [4–6]. The noninsulinoma 
pancreatogenous hypoglycaemia due to beta-cell hyperpla-
sia is another even rarer cause, accounting for 4 % of all 
cases of HH [7]. Recently, it has been increasingly reported 
in patients who have undergone a gastric bypass for severe 
obesity. Furthermore, autoimmune hypoglycaemia due 
to insulin antibodies or insulin receptor antibodies must 
be taken into account in the differential diagnosis of HH 
to avoid misleading diagnosis of insulinoma. Treatment of 
HH is challenging due to the rarity of this condition and 
the difficulty of a correct diagnosis, mainly that of the less 
frequent form of HH. The aim of this review is to give an 
overview of the recent literature on the management of HH.
Treatment of benign insulinoma
Surgery
The surgical resection of insulinoma represents the treat-
ment of choice since most tumours are small (<2 cm) and 
benign [8, 9]. The tumour enucleation, using an open or 
laparoscopy approach, is the advisable option whenever 
possible [10–18]. The successful surgical rate ranges from 
75 to 98 %. Given the multiplicity and the risk of malig-
nancy of insulinomas in MEN1 patients, the choice of 
which surgical approach to perform is debatable. Pancre-
atic resections are suggested by several authors in order to 
provide long-term cure [13, 19, 20]. However, due to lower 
morbidity enucleation of all insulinomas might be con-
sidered as an alternative to distal or total pancreatectomy 
[10, 21, 22]. The relapse rate of insulinoma after surgery is 
low (3–7 %) in sporadic cases compared to MEN1 patients 
(21 %) after a 20-year follow-up [12–23]. In the last few 
years, robotic-assisted techniques have become feasible 
also for the resection of small pNETs, including insulinoma 
[10, 11]. However, the surgical indications and results are 
still ongoing [24].
Local–regional ablative therapy
In patients at high surgical risk or in those refusing surgery, 
alternative local regional therapies can be offered. Several 
case reports and small series have been published reporting 
successful treatment of hypoglycaemia by transcutaneous 
or laparoscopically radiofrequency ablation, high-intensity 
focused ultrasound ablation (HIFU), ultrasound-assisted 
alcoholization or selective chemoembolization [25–32]. 
However, follow-up of patients treated with locoregional 
therapies is generally short, ranging from 5 weeks to 
9 months; thus, additional data are needed to validate these 
techniques.
Hypoglycaemia symptomatic therapy
During the pre-operative phase, 10 % glucose solution is 
usually administered and continued for an additional 24-h 
period after surgery. Serum glucose levels typically rise 1 h 
after the successful removal of the insulinoma, but in 20 % 
of cases the glucose increase can be delayed [5].
Patients waiting for the operation, or who are not candi-
dates for or refuse surgery, or in whom surgical treatment 
has not been successful, can be treated medically to con-
trol the hypoglycaemic episodes [33]. Besides pharmaco-
logical treatment, patients should follow a fractioned diet 
including complex carbohydrates with slow absorption and 
simplex carbohydrate with fast absorption in case of hypo-
glycaemic crisis. Diazoxide, the most used drug, inhibits 
insulin release by opening the ATP-dependent potassium 
channel in pancreatic β cells. It is effective in control-
ling the hypoglycaemic episodes in more than half of the 
patients in fractioned doses ranging from 100 to 600 mg up 
to 1500 mg per day [34]. Because of the sodium retention 
side effect, it is often given in association with a thiazidic 
diuretic. Moreover, it can provoke gastrointestinal side 
effects such as nausea and vomiting and hirsutism [35].
Given the inhibitory effect of insulin secretion by soma-
tostatin analogues and the presence of somatostatin recep-
tors (SSTR)2A-SSTR5 in a subgroup of insulinomas, 
octreotide has been demonstrated as an effective treat-
ment of hypoglycaemia in about 50 % of patients. A posi-
tive short test with subcutaneous octreotide is predictive 
of the efficacy of the treatment, while a positive result of 
Octreoscan scintigraphy is not predictive [36, 37]. Moreo-
ver, the test is useful to predict a paradoxical worsening 
of hypoglycaemia that can occur due to the suppression 
of the counter-regulatory hormones glucagon and growth 
hormone, mainly during treatment with long-acting soma-
tostatin analogues [38, 39]. In the case of a malignant insu-
linomas, somatostatin analogues have been reported as less 
effective [35].
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SSTR subtype expression differs between benign and 
malignant insulinomas, even though there are conflict-
ing data [40]. Bertherat et al. [41] found that SSTR2 and 
SSTR5 are the most frequently expressed SSTRs in insu-
linomas. In most of the tumours they investigated, that were 
mainly benign, higher expression of SSTR2 than of SSTR5 
was observed, but a subgroup of tumours presented higher 
expression of SSTR5 than of SSTR2. Portela-Gomes et al. 
[42] found that SSTR4 was the most frequently expressed 
SSTR in both benign and malignant insulinomas. The 
malignant tumours, but none of the benign tumours, also 
expressed SSTR5. In this series, all other receptor sub-
types were expressed in low numbers, and no difference 
between benign and malignant insulinomas was found. In 
the study by de Sá et al. [40] SSTR5 mRNA was positively 
correlated with histopathological features related to tumour 
aggressiveness (large tumour diameter, well-differentiated 
endocrine tumour with uncertain behaviour and higher 
number of cells with nuclear atypia). Finally, in malignant 
insulinomas a higher expression of SSTR compared with 
benign insulinomas has been described [43].
Finally, in the case of refractory hypoglycaemia, treat-
ment with glucocorticoids can be used because it induces 
hyperglycaemia by inhibiting insulin release and increasing 
peripheral insulin resistance [33].
Treatment of refractory hypoglycaemia 
in malignant insulinoma
Malignant insulinoma accounts for 10 % of all cases of 
insulinoma. It displays a poor prognosis and represents a 
double therapeutic challenge for clinicians: the control of 
tumour progression and the control of severe hypoglycae-
mic syndrome. The risk of hormone-related death or com-
plications makes symptoms control of primary importance.
Recently, a better understanding of molecular pathways 
has provided clues for new therapeutic strategies and a 
variety of targeted agents have been explored in pNETs.
Hormonal syndrome control
Everolimus
Everolimus acts as inhibitor of mTOR signalling pathway, 
which plays a key role in the control of cell growth, prolifer-
ation as well as lipid and glucose metabolism [44, 45]. This 
oral anticancer drug has recently been shown to improve 
progression-free survival of patients with well-differentiated 
progressive metastatic pNET (RADIANT III study) [46] 
and has been approved by FDA in 2011 for this indication 
[47]. It may have synergistic antitumour effects when com-
bined with somatostatin analogues [48]. In several studies 
hyperglycaemia and diabetes have been recognized as a fre-
quent adverse event of everolimus [46, 49, 50], making the 
drug appealing to the management of insulinoma.
Initial case reports and small series of patients with insu-
linoma and untreatable hypoglycaemia found that everoli-
mus was able to induce a rapid normalization of blood 
glucose levels in a few days, allowing glucose infusion to 
discontinue in several cases or the withdrawal of all other 
treatments for several months [45, 51–54]. The French 
Group of Endocrine Tumors has recently shown that 11 
out of 12 patients with metastatic insulinomas and refrac-
tory hypoglycaemia had a complete clinical response with 
everolimus treatment, although they previously experienced 
a median failure of four different treatment lines [55].
The exact mechanism by which everolimus can control 
hypoglycaemia in patients with insulinoma is not fully 
elucidated, and several mechanisms can be considered, 
including an increase in peripheral insulin resistance and a 
decrease in beta-cell proliferation, survival and metabolism 
[45, 49]. The effect of everolimus in insulinoma-induced 
hypoglycaemia has also been reported in patients who 
did not have tumour regression [51, 55, 56], suggesting 
that disease progression and/or increased levels of insulin 
may not be considered the only criteria for discontinuing 
everolimus therapy when hypoglycaemia is controlled [57].
Sunitinib
Sunitinib, a multiple tyrosine kinase inhibitor that target 
vascular endothelial growth factor receptor and platelet-
derived growth factor receptor [56, 58], is another oral 
anticancer agent approved in the treatment of progressive 
advanced pNET [59]. Unlike everolimus this drug does not 
have direct effects on glycaemic control. Some studies even 
reported the risk of onset of severe hypoglycaemia with 
sunitinib [60, 61], making its use in the treatment of malig-
nant insulinoma still questionable [62, 63].
Interferon‑α
Interferon-α (IFN-α) is a biological agent with direct action 
on cell cycling, angiogenesis and modulation of immune 
response. The drug has antisecretory and antiproliferative 
efficacy in NET, similar to those of somatostatin analogues 
[64]. However, INF-α does not act as rapidly as somatostatin 
analogues and has a less favourable safety profile, with com-
monly reported adverse events such as fever, fatigue, ano-
rexia and weight loss [58]. Due to toxicity profile, the drug 
mainly is a role as a second-line option in the refractory set-
ting [64, 65]. INF-α is not generally recommend in the treat-
ment of insulinoma. Indeed, the use of INF-α in the treat-
ment of malignant insulinoma was reported only in the past, 
as anecdotal experiences [66], without proof of real efficacy.
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Pasireotide
Pasireotide (SOM230) is a new multi-receptor-targeted 
somatostatin analogue. As compared with octreotide, 
pasireotide exhibits a binding affinity 30–40 times higher 
for human SSTR1 and SSTR5 and 2.5 lower for human 
SSTR2. Owing to the promising results obtained in the 
treatment of patients with acromegaly and Cushing’s syn-
drome, investigation on NETs was initiated. The most 
frequent adverse events reported were nausea, abdominal 
pain and hyperglycaemia. In particular, a recent phase II 
trial with pasireotide long acting conducted in grade 1 or 
2 NETs reported a 79 % rate of hyperglycaemia, including 
14 % of grade 3 hyperglycaemia [67]. The hyperglycaemic 
effect of pasireotide, greater than other somatostatin ana-
logues (octreotide, lanreotide), can be explained by the dif-
ferent binding affinities of pasireotide to SSTRs and by the 
subtype-selective expression of SSTRs in pancreatic islet 
cells. Immunocytochemistry study showed that SSTR1 and 
SSTR5 were co-localized with insulin in almost all β cells, 
whereas SSTR2 was found in only 46 % of β cells. Con-
versely, SSTR2 was co-localized with glucagon in most of 
α cells [68]. Thus, pasireotide, with a high binding affin-
ity to SSTR1 and SSTR5, exhibits a strong inhibitory effect 
of insulin secretion with no significant effect on glucagon 
release.
Currently, pasireotide is still not registered for the treat-
ment of NET and we are waiting for the results of ongoing 
trials.
Given that SSTR1 and SSTR5 may have an inhibitory 
effect on cell proliferation and that SSTR5 is involved in 
insulin secretion control [69], SOM230 would have the 
potential to promote size reduction and inhibition of insulin 
secretion in insulinomas [40].
Studies on pNET in mouse model have indeed shown 
the antisecretory, antiproliferative and proapoptotic activity 
of the drug in MEN1 model of insulinoma [70, 71]. Moreo-
ver, a paper was recently published reporting the efficacy of 
pasireotide in treatment of refractory hypoglycaemia due to 
malignant insulinoma [72].
On the basis of these preliminary data, pasireotide could 
be considered a novel therapeutic option for symptom con-
trol in malignant insulinoma. However, further studies on 
its effects in refractory hypoglycaemia are warranted.
Antineoplastic treatment
Chemotherapy
Chemotherapy has a critical role in the management of 
metastatic and progressive insulinomas. A variety of sys-
temic chemotherapy regimens have been explored in 
patients with pNETs, including insulinomas. streptozotocin 
combined with 5-fluorouracil (FU) and/or doxorubicin 
has been used, resulting in objective response (OR) in 
6–70 % of patients with pNETs [73–77]. The combination 
of capecitabine and temozolomide has also been evalu-
ated, and OR of 70 %, a median progression-free survival 
(PFS) of 18 months and 2-year survival of 92 % have been 
reported [78]. Favourable results have also been obtained, 
testing dacarbazine as a second-line therapy. Dacarbazine 
alone achieved an OR of 34 % [79], while in combination 
with 5-FU and epirubicin, the OR was 20–40 % and the 
PFS 11–21 months [80]. In addition, recent studies evalu-
ated the use of combined gemcitabine and oxaliplatin as 
first-line treatment in 37 patients with pNETs, resulting in 
OR in 38 % of patients and PFS of 7.3 months [81]. How-
ever, the above-mentioned studies are limited regarding the 
evaluation of the effects of chemotherapy on patients with 
all types of pNETs, while specific data on insulinomas are 
lacking. Generally, nonfunctioning pNETs are overrepre-
sented in these studies, while malignant insulinomas are 
rare and not even included in the studies.
Debulking surgery
Cytoreductive surgery, when feasible, may decrease the 
hormonal secretion and also makes systemic therapy more 
effective. Thus, in advanced malignant insulinoma pallia-
tive surgery to remove or debulk the primary tumour is rec-
ommended, but depends on its location and extension into 
surrounding tissues [58]. Mesenteric artery invasion is a 
contraindication to surgery [62], and at least 90 % resec-
tion of the tumour is typically required to achieve symptom 
control [58]. Improved outcome has been demonstrated 
in patients with islet cell cancer and synchronous hepatic 
metastases managed aggressively with debulking surgery 
[82, 83].
Surgery of liver metastases is of interest when more than 
90–95 % of the macroscopic tumour mass can be removed 
and/or hypoglycaemic syndrome is refractory. In certain 
cases of severe hypoglycaemia, less ambitious surgery is 
undertaken, resecting 60–70 % of the liver metastases. The 
benefit however remains undetermined [62].
Liver metastases cytoreductive therapy (HAE/TACE, SIRT)
Metastatic involvement of the liver typically develops in 
about 46–93 % of NETs [84]. P-NETs show liver metas-
tases either at initial evaluation or during the course of 
their disease in 30–85 %. About 10 % of insulinoma pre-
sent liver metastases [85]. Presence and extension of liver 
metastases are considered important prognostic factors for 
NETs as they may significantly impair the patient’s quality 
of life either because of tumour bulk or hormonal hyper-
secretion [86]. Liver metastases can result in a gradual 
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replacement of liver parenchyma resulting in a progressive 
deficit of function until death, thus decreasing long-term 
survival. Treatment of liver metastases can be curative or 
palliative. An effective treatment has to result in control of 
tumour growth and systemic hormonal effect, improvement 
of quality of life. In most NETs patients with liver metas-
tases, minimally invasive, locoregional approaches are 
adopted in place of surgery which remains the first option 
if possible. They include trans-arterial embolization (TAE), 
trans-arterial chemoembolization (TACE), selective inter-
nal radiation therapy (SIRT) [87].
TAE is based on selective infusion of particles in the 
branch (segmental or subsegmental) of the hepatic artery 
supplying the tumour lesions. The goal of TAE is to 
occlude tumour blood vessels resulting in ischaemia and 
necrosis. TACE differs from TAE for the administration of 
a chemotherapeutic agent (anthracyclines such as doxoru-
bicin or epirubicin) mixed with lipiodol (fat-soluble con-
trast medium with high concentration of iodine), into the 
hepatic artery followed by the administration of embolizing 
agents. In TAE treatment, lipiodol administration (50 %) is 
followed by the administration of embolizing agents [88].
Indications for TAE/TACE generally include unresect-
ability with symptoms related to tumour bulk, excessive 
hormone production and rapid progression of liver disease. 
Many reviews have been published on locoregional ablative 
treatments of liver metastases of all NETs and reported that 
TAE and TACE appear to be an optimal treatment approach 
for inoperable liver metastases from NETs for palliation of 
hormonal symptoms and pain, improvement of biomarkers 
and reduction of tumour burden [87–89]. A growing inter-
est in local treatment options lies in the use of SIRT using 
yttrium-90 (90Y). 90Y is high-energy β-emitter with a mean 
tissue penetrance of 2.5 mm. This is attached to microspheres 
measuring 20–40 um in size. Due to the local application, 
a radiation dose of up to 1000 Gy can be administered to 
the tumour, causing local destruction. As this is a relatively 
new method, only a few studies exist, showing a 1-year sta-
ble disease in 60–67 % and a primary relief in symptoms in 
roughly 80 % of patients. In those studies, especially patients 
with large volume tumours were included [90]. However, to 
clarify the value of these regimens in the treatment of hepatic 
metastases, further investigation is warranted.
Regarding insulinoma, liver metastases are the major 
cause of post-operatively persistent hypoglycaemia, 
although due to the small number of metastatic insulino-
mas, no controlled studies of the therapeutic effect of the 
above-mentioned interventions exist for this specific kind 
of tumour. Infrequent case reports that include one or sev-
eral patients and feature unusual aspects of the disease 
are available. Affected patients are usually included with 
other NET patients in study protocols intended to evaluate 
the effectiveness of chemotherapy or adjuvant treatments 
such as somatostatin analogues [91, 92]. Satrke et al. [93] 
reported on 10 patients with metastatic malignant insu-
linoma, treated with repeated TACE and chemoperfusion 
protocols using high-dose transhepatic streptozotocin per-
fusions (3–4 g per session). The current median survival 
time for all 10 patients is 2.6 years (range 1.6–9.7 years). 
Six patients are currently alive with a median survival of 
3.7 years (1.7–9.7 years), five of them with stable dis-
ease and free of hypoglycaemia. Four patients died after 
a median survival of 1.8 years (range 1.6–7.5 years) from 
complications of unmanageable hypoglycaemia.
Peptide receptor radionuclide therapy (PRRT)
PRRT uses somatostatin analogues coupled with β-emitting 
radionuclides yttrium (90Y) and lutetium (177Lu), which 
internalized within neuroendocrine cells after their bind-
ing to the SSTR [62]. Yttrium and lutetium differ from one 
another in terms of emitted particles, particle energy and 
tissue penetration.
As a prerequisite for this therapy, the presence of SSTR 
subtypes on tumour cells has to be demonstrated. For this 
purpose, in vivo 111In-pentetreotide scintigraphy, or 68Ga-
DOTANOC PET, and SSTR immunohistochemistry on 
tumour specimens have been used [56]. To maximize the 
effect of therapy, treatment with short-acting somatostatin 
analogues has to be discontinued 1 day before PRRT and 
6 weeks by the treatment with long-acting somatostatin 
analogues. PRRT is arising as effective treatment in GEP–
NETs with promising results in nonrandomized trials, 
including pNET [94, 95]. Symptomatic responses to PRRT 
have been observed in case of malignant insulinoma with 
refractory hypoglycaemia [52, 96, 97], also when objective 
measurable tumour response was minimal or absent [56]. 
The main long-term side effects reported were loss of renal 
function, pancytopenia and myelodysplastic syndrome. 
Age exceeding 70 years, bone metastasis, previous chem-
otherapy and creatinine clearance less than 60 ml/min are 
predictive factors for higher toxicity [62].
PRRT can be considered as an important therapeutic 
option in case of refractory hypoglycaemia due to malignant 
insulinoma, although currently the treatment is still deemed 
as investigational and its implementation must comply with 
national legislation and ethical guidelines [98].
Treatment of noninsulinoma pancreatogenous 
hypoglycaemia
Nesidioblastosis
In 1938, Laidlaw described nesidioblastosis as a functional 
disorder of non-neoplastic beta cells [99] characterized by 
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combined hyperplasia, diffuse proliferation and hypertro-
phy of islet cells from pancreatic ducts [100, 101]. This 
clinical entity, also referred as noninsulinoma pancreatog-
enous hypoglycaemia syndrome (NIPHS), currently rep-
resents 0.5–5 % of organic hyperinsulinemia causes [102]. 
Diagnostic criteria for NIPHS include positive Whipple’s 
triad, a negative 72-h fast, negative perioperative imaging 
studies for insulinoma, positive arterial calcium stimula-
tion test [103] and islet hypertrophy or nesidioblastosis in 
pancreatic tissue [101]. NIHPS has been identified both 
in patients with idiopathic nesidioblastosis and in patients 
who had upper digestive bariatric surgery. Idiopathic 
nesidioblastosis is generally secondary to genetic abnor-
malities such as the mutations in SUR1 and Kir6.2 genes, 
which encode proteins involved in beta-cell function [104, 
105]. However, these genetic abnormalities have not been 
described in adults [101, 106], even though other genetic 
mutations, as yet unspecified, might be supposed. Alterna-
tively, it has been suggested that calcium ions may directly 
trigger the release of β-cell peptides from tumourous β 
cells by a, yet undefined, mechanism not shared by normal 
β cells [107]. Currently, subtotal esophagectomy, subtotal 
gastrectomy, roux-en-Y gastric bypass (RYGB), Billroth I 
partial gastrectomy and Billroth II gastric bypass surgeries 
have all been associated with NIPHS, while gastric banding 
procedures have been shown to induce transient asympto-
matic HH [108–110]. The phenomenon of hypoglycaemia 
in post-RYGB patients is becoming increasingly com-
mon, and a prevalence of 0.36 % has estimated. At least 
40 cases of nesidioblastosis have currently been reported 
after RYGB [108, 111]. However, the pathogenetic mech-
anisms of nesidioblastosis in post-RYGB patients are not 
fully understood. On the one hand, the change in gastro-
intestinal architecture might contribute to the pathogenesis 
of NIPHS [112]. On the other hand, the consequent weight 
loss and reduction of insulin resistance might unmask a pri-
mary underlying condition [113, 114]. In this view are the 
findings that some patients with RYGB history did not have 
histologic criteria for nesidioblastosis [115], suggesting 
that some patients might have a pre-nesidioblastosis lesion 
prior to their surgery, due to genetic or obesity-related 
effects [116]. Therefore, potential mechanisms of acquired 
nesidioblastosis after gastric bypass include obesity-
induced adaptive beta-cell hypertrophy, increased growth 
factors release and altered gut hormonal signalling [108, 
111, 115–119]. Glucagon-like peptide-1 (GLP-1) might 
play a crucial role, inducing the expression of the transcrip-
tion factor pancreatic-duodenum homeobox-1 (PDX-1) that 
regulates islet growth [120]. Further, other factors such as 
IGF-2, IGF-1 alpha receptor, TGF beta receptor and ghrelin 
might be involved in nesidioblastosis pathogenesis [118]. 
Medical treatment, consisting of low-carbohydrate diet in 
combination with compounds such as diazoxide, octreo-
tide, acarbose or calcium channel blockers (such as vera-
pamil and nifedipine), should be first started [121–124]. 
However, distal, subtotal and near-total pancreatectomy in 
severe cases of nesidioblastosis and in patients with history 
of upper gastrointestinal surgery might be required [110, 
117, 125] (Tables 1, 2).
Autoimmune hypoglycaemia
Autoimmune hypoglycaemia is characterized by elevated 
levels of insulin, hypoglycaemia and anti-insulin antibodies 
(insulin autoimmune syndrome, Hirata syndrome) or anti-
insulin receptor antibodies (type B insulin resistance). In 
these syndromes are present postprandial hypoglycaemia, 
fasting hypoglycaemia or both [126].
Hirata syndrome is a rare condition in Western coun-
tries, whereas in Japan it is the third cause of hypogly-
caemia [127]. Episodes of HH mainly in the postprandial 
phase are present. This condition is associated with the 
presence of anti-insulin antibodies that cause postprandial 
Table 1  Causes of 
hypoglycaemia in adults Ill or medicated individual
1. Drug or alcohol assumptions (insulin or other insulin secretagogues)
2. Critical illnesses: hepatic, renal or cardiac failure, sepsis
3. Hormone deficiency: cortisol, glucagon and epinephrine in type 1 diabetes mellitus
4. Nonislet cell tumours
Apparently healthy individual (hyperinsulinemic hypoglycaemia)
1. Insulinoma
2. Noninsulinoma pancreatogenous hypoglycaemia:
 a. Idiopathic nesidioblastosis
 b. Upper gastrointestinal surgery hypoglycaemia
3. Autoimmune hypoglycaemia:
 a. Anti-insulin antibodies (insulin autoimmune syndrome or Hirata syndrome)
 b. Anti-insulin receptor antibodies (type B insulin resistance)
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hyperglycaemia; as the glucose levels decrease the insulin 
bound to antibodies is released, resulting in inappropriately 
high free insulin concentration that causes hypoglycaemia 
[128]. Systemic lupus erythematosus, benign monoclonal 
gammopathy and multiple myeloma are often associated. 
Methimazole treatment may be associated with the dis-
ease [129, 130]. In Hirata syndrome, the insulin levels are 
elevated, usually above 100 µU/mL, such as C-peptide and 
proinsulin, and insulin antibodies show a high percentage 
of binding to insulin [131]. Type B insulin resistance syn-
drome is characterized by severe hyperglycaemia, acantho-
sis nigricans and fasting hypoglycaemia episodes. The anti-
insulin receptor antibodies are the cause of this syndrome, 
and it is more frequent in black young women [132]. At 
low titres, the antibodies act as partial agonists resulting in 
hypoglycaemia; at high titres they downregulate the recep-
tor’s response to insulin causing hyperglycaemia [133]. In 
this syndrome insulin levels, C-peptide and proinsulin are 
moderately elevated, and insulin receptor antibodies are 
present [126]. Type B insulin resistance is often associated 
with rheumatologic and hematologic diseases. Currently, 
there are nonstandard therapies for treating autoimmune 
forms of hypoglycaemia. In Hirata syndrome, a spontane-
ous remission of hypoglycaemia can be observed within 
3–6 months of diagnosis. Anyway in this syndrome the 
response to therapy is usually good [134]. The first treat-
ment is based on small frequent meals low in carbohydrate 
to prevent postprandial hypoglycaemia. Steroids, in particu-
lar oral prednisone (30–60 mg/day), would seem to solve 
the symptoms of hypoglycaemia [135]. Other therapeutic 
options such as acarbose (to decrease glucose absorption), 
diazoxide and octreotide have demonstrated partial benefit 
in the management of this syndrome. The pancreatectomy 
should be considered in the presence of intractable hypo-
glycaemia [126]. A case of Hirata syndrome treated with 
plasmapheresis was reported, showing the regression of 
hypoglycaemia and the gradual disappearance of antibod-
ies within a few months [136]. In type B insulin resistance 
the therapeutic approach is more complex and not fully 
understood, and the treatment is based on steroid therapy 
or immunosuppressant agents [137]. The improvement of 
hypoglycaemia, and the decrease in antibodies, in a patient 
with type B insulin resistance, after a first line of treatment 
with high dose of steroids (prednisone 80 mg/day), fol-
lowed by the addiction of azathioprine (100 mg/day) and 
the gradually steroids reduction (7.5 mg/day) [138] was 
reported. Arioglu et al. [139] reviewed the long-term clini-
cal course of type B insulin resistance syndrome and con-
cluded that the most effective treatment of type B insulin 
is a short-term high steroid dose therapy. A new therapeu-
tic protocol was reported with an intensive combination of 
rituximab, cyclophosphamide and pulse corticosteroids, 
showing after 8 months of the treatment the remission of 
symptoms [140].
Conclusions
A correct differential diagnosis, mainly with the rarest forms 
of HH, is fundamental to perform an adequate treatment and 
to avoid unnecessary surgical treatment. When a benign 
insulinoma has been diagnosed, surgery is the first option, 
Table 2  Medical treatment of hyperinsulinemic hypoglycaemia (HH) according to the pathology
Cause of HH Treatments References
Benign insulinoma Diazoxide (from 100 to 600 mg up to 1500 mg per day) Gill et al. [34]
Somatostatin analogues Vezzosi D et al. [36]
Steroids De Herder WW et al. [33]
Malignant insulinoma Everolimus Bernard et al. [55]
Sunitinib De herder WW et al. [56]
Chemotherapy Eriksson et al. [80]
Peptide receptor radionuclide therapy (PRRT) Baudin et al. [62]
Nesidioblastosis Diazoxide, octreotide, alpha-glucosidase inhibitors 
(acarbose) or calcium channel blockers (verapamil 
and nifedipine)
Kapoor et al. [124]
Hirata syndrome Steroids (prednisone, 30–60 mg/day) Wong et al. [135]
Plasmapheresis Yaturu et al. [136]
Autoimmune hypoglycaemia type B Steroids (prednisone 80 mg/day), azathioprine 
(100 mg/day)
Chon et al. [138]
Combination of rituximab, cyclophosphamide and 
pulse steroids
Malek et al. [140]
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with the mini-invasive approach, whenever possible. The 
management of malignant insulinoma is often multimodal 
and aimed to symptom and tumour control. Everolimus can 
represent the main treatment in refractory hypoglycaemic 
syndrome control, regardless of the anti-neoplastic response 
and insulin levels. Diet and medical therapy of hyperinsu-
linemia may provide relief in the most part of patients with 
suspected nesidioblastosis, even though for those patients 
who fail medical therapy, the surgical treatment with pan-
createctomy or the conversion to a restrictive form of bariat-
ric procedure should be recommended. Autoimmune forms 
of hypoglycaemia are uncommon, therapies are complex, 
and the results in the literature are controversial. However, if 
spontaneous remission is possible for Hirata syndrome, ster-
oid and immunosuppressive agents may be considered the 
most effective therapy for type B insulin resistance.
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